Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Arrieta OscarRodrigo CatalánSilvia Guzmán-VazquezFeliciano BarrónLuis Lara-MejíaHerman Soto-MolinaMaritza Ramos-RamírezDiana Flores-EstradaJaime de la GarzaPublished in: BMC cancer (2020)
In our population, erlotinib, afatinib, and gefitinib were statistically equally effective in terms of OS and PFS for the treatment of patients with advanced EGFR-mutated NSCLC population. Owing to its marginally increased PFS and OS, the cost-effectiveness analysis determined that afatinib was a slightly better cost-effective option when compared with first-generation TKIs (erlotinib and gefitinib).